Member Info for leas

willec, that pattern has been the same for quite a while. As I have posted before that a false picture is being painted here. It will end and maybe more news will be the catalyst but imo someone is accumulating. I can wait.

No news, shares in issue change resulting in percentage adjustment. I wonder if Woodford buys more to take him back to 29%. :)

Afternoon Jersey. Share price is slightly up on yesterday's close. It was the UT yesterday that lifted the close giving the perception of weakness today.

Stockboy, he has been selling for months and months. His motivation to sell is not driven by anything other than ego. We all know he is well under 3% now but it is still having a overhang on the sp. He will be gone soon enough and I will thank him for allowing me to buy a big chunk at 10.5

Another 500k shares bought at avg of 17.55.... false picture being painted here. There is no weakness despite the colour red.

Certainly some fun and games being played here. Some positioning going on. Love to have a live view of the share registry.

Thanks cash.. from that article

'We also botched the 2014-5 season, when new strains hadn’t been included in the vaccine. That season the vaccine was a measly 19% effective, compared to over 50% in the previous year. Early on in the 2017-8 influenza season, there were near-record numbers of hospitalisations, and though the latest vaccine’s performance improved throughout the season, overall effectiveness is estimated to have been 40%.

Hmmm, what was the success rate of FLU-5. 84%. As the company stated, groundbreaking!

Jimzi, looking at the SEEK group and their experience, I would think that they are 'driving' any deals. Not as accountable as HVIVO are to shareholders and not as likely to roll over. I see on their website it says that there strategy is to grow the business through development and acquisitions. Just hope that they are not the enemy within. Woodford and the likes will make sure any deal has the interests of the shareholders at the fore.

Donald, forgot about the Fed govt. Shutdown. Maybe implications for other UK bios looking at getting NDA approval.

Grailor, I was invested in IMM for many years and imo it was the design of the P3 trial that failed. Their inexperienced showed, not just in the recruitment but the reduction the FDA wanted to see in the SLEDIA scale. Hence my decision to take the money and run prior to the completion of the trial.

I thought that they would have to complete P3 successfully before any application can be made as it has to be signed off. In any case, would it not be better for a company experienced in taking a drug to market be the ones in discussions with the regulatory bodies outlining the design of the trial.

Grailor, maybe the company's strategy is to negotiate a deal prior to the P3 trial. Have to agree that I cannot see FLU-v being commercial next year but that said, I cannot see it sitting on the shelf when the results were so convincing from their P11b trial. They have already stated that they are looking for a partner to take it further which I totally agree with. In the short to medium term that is were the value lies for shareholders sub 100p. Of course those taking a long term view could reasonably expect much more capitol growth when any vaccine is sold.
As for news, well that is speculation but any negotiations will be subject to non disclosure which is normal practice in this industry.
I will add that this is my opinion and as frustrating as the last few months have been I do believe that the company will deliver on it's potential.

TradingT, many treatments now are being developed around stimulating a patients own autoimmune system to fight infections and viruses. HVO are not developing antibiotics, or at least not one of their lead products but the treatment is about stimulating an immune response mediated through T-cells and B-cells.
Today's news is probably more of interest to bios such as Motif bio but it does illustrate the need to develop new forms of treatments which we have taken for granted in the past. FLU-v will stimulate our own immune system to fight the virus and reduce antibiotic dependency.

Spudding news expected any day now. Initiated by ONGC progress.

I don't see the need to have a higher intellect to day trade. Some may consider them to be gamblers rather than investors.
Some chunky sales going through. So holding up well, more of them we see, the quicker we will see the back of our seller.
Tick tock...

Nice opportunity for the staff to benefit from the rewards a deal will bring.

Niles, I think the production drop off is recognised. I think (together with our seller) the market valued the company accordingly. At 9.5p you could argue it was at a discount. However, recent news and strategy has shifted the focus away from Plat. I'm not saying that is right but we also have to be flexible on priorities now that we have other partners to consider. There is a risk that we do too much too fast and maybe their approach is more measured.

I don't think it is necessarily a bad thing that we have not moved much higher. Still lots to digest, more news due anytime on Caleo-1. Probable overhang of remaining shares held by RH. I think it's safe to say, whatever the views of investors are the sp is only going one way. Not looking to trade this so happy to sit back and let the market catch up with the improving fundamentals.

3putt, 'end of January'. Absolutely, so could be today or next week as our partners dictate the pace. Also news on SOL-1 which could be brought forward as it is drill ready.

sp will take care of itself. Lots to digest so did not expect instant gratification. Should get some good PR as the week progresses. On a plus side traders will ne frustrated without the herd causing a spike but the rerate will come.